Stott H, Stephens R, Fox W, Simon G, Roy D C
Thorax. 1976 Jun;31(3):265-70. doi: 10.1136/thx.31.3.265.
A standard series of radiographs of 588 patients allocated at random to treatment with busulphan (B patients), cyclophosphamide (C patients), or a placebo (P patients) for two years after surgery for bronchial carcinoma were viewed in three stages (following procedures which avoided bias) by an independent assessor, unaware of the allocated treatment of any patient, with a view to identifying pulmonary changes due to busulphan. Radiographic appearances consistent with busulphan lung were not reported in any of the 195 B patients (receiving a mean dosage of 464 mg of busulphan over 301 days) or of the 192 C patients but were present in one of the 201 patients receiving placebo.
对588例支气管癌手术后随机分配接受白消安治疗(B组患者)、环磷酰胺治疗(C组患者)或安慰剂治疗(P组患者)的患者进行了标准系列的X光片检查,为期两年。一名独立评估人员分三个阶段(遵循避免偏差的程序)查看这些X光片,该评估人员不知道任何患者的分配治疗情况,目的是识别白消安引起的肺部变化。在195例B组患者(在301天内平均接受464毫克白消安剂量)或192例C组患者中,均未报告与白消安肺相符的X光表现,但在201例接受安慰剂治疗的患者中有1例出现了这种表现。